In contrast, the growth inhibitory effect of combined treatment of γ-tocotrienol with PPARγ antagonists, GW9662, and T0070907 were found to be statistically synergistic in both MCF-7 (Figure 4(a)) and MDA-MB-231 (Figure 4(b)) breast cancer cells, as evidenced by the location of the data point in the isobologram being well below the line defining additive effect. This evidence concerns the gene PPARG and breast carcinoma.